Exogenous RNAi triggers such as shRNAs ideally exert their activities exclusively via the
antisense strand that binds and silences designated target mRNAs. However, in principle …

Direct‐acting antivirals (DAAs) are modern treatments for chronic hepatitis C infection, but
majority of available evidence on its treatment effect covers genotypes 1 to 4. Therefore, the …

Aims: We aimed to examine changes in skeletal muscle mass in chronic hepatitis C (CHC)
patients undergoing interferon (IFN)-free direct acting antivirals (DAAs) therapy who …

Objectives: To estimate clinical outcomes and cost-effectiveness of ombitasvir/paritaprevir/
ritonavir and dasabuvir±ribavirin (OMB/PTV/r+ DSV±RBV) compared with treatment …

Introduction The recent availability of highly effective, easily administered, and relatively
nontoxic treatments for hepatitis C virus (HCV) infection provides an opportunity for …

Hepatitis C is a global public health problem, and the aim of this study was to understand the
experiences of patients with hepatitis C using second-generation antivirals. In-depth …

Background: The treatment of chronic hepatitis C virus infection has been revolutionized by
the advent of direct-acting antiviral agents. However, evidence of its effects on patients with …

In the previous parts of the series the antiviral agents used in genital herpes, genital HPV
infection and therapeutic options in HIV infections were presented. The sexual contact is one …

AIM: To compare efficacy of telaprevir (TVR) and simeprevir (SMV) combined with pegylated
interferon (PEG-IFN) and ribavirin (RBV) while treating chronic hepatitis C (CHC) …

Objective Limited evidence is available on predictors of medical resource utilization (MRU)
and related direct costs, especially in treatment-experienced patients infected with genotype …